Wockhardt profit and loss

Latest FY26
Revenue
₹3,373cr+12.0% on FY25
EBITDA
₹652cr+65.9% on FY25
Net profit
₹199cr−₹57.0 cr in FY25
EPS
₹13.12−₹3.02 in FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
3,5643,3733,0122,7982,651
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
12211162.083.0122
3,6863,4843,0742,8812,773
Expenses
739674612620518
555586573559509
−106−128−53.0−14.084.0
757725651629637
217213254305302
226227217223251
847864836965802
3,2353,1613,0903,2873,103
77265239339.0101
546425176−184−150
Profit
451323−16.0−406−330
12.0−85.00.0−14.0−294
463238−16.0−420−624
21.018.07.016.012.0
28.021.034.036.0−15.0
49.039.041.052.0−3.0
414199−57.0−472−621
414199−57.0−472−621
28541971.06.078.0
69961814.0−466−543
409213−47.0−463−559
5.0−14.0−10.0−9.0−62.0
Per share
₹25.20₹13.12−₹3.02−₹32.05−₹38.79
₹25.19₹13.10−₹3.02−₹32.05−₹38.79
Other comprehensive income — detail
28541971.0——
70.070.0−5.0−8.0−9.0
21534976.014.087.0
64858113.0−461−498
51.037.01.0−5.0−45.0
Per share — as-filed variants
₹25.20₹13.12−₹3.02−₹32.05−₹38.79
₹25.19₹13.10−₹3.02−₹32.05−₹38.79
Derived — gross profit (revenue − materials − purchases − Δ inventories)
2,3762,2411,8801,6331,540
66.7%66.4%62.4%58.4%58.1%
Adjusted (ex-exceptional items) — derived
451323−16.0−406−330
12.0−85.00.0−14.0−294
403270−57.0−458−328
₹24.55₹17.81−₹3.02−₹31.10−₹20.51
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

WOCKPHARMA₹1,922.90

Wockhardt Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersBIOCONSYNGENEASTERDMGLANDPPLPHARMACOHANCELALPATHLABNATCOPHARMMcap ₹31,151 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations2,651.02,798.03,012.03,373.03,564.0
Other Income122.083.062.0111.0122.0
Total Income2,773.02,881.03,074.03,484.03,686.0
Expenses
+ Cost of Materials Consumed518.0620.0612.0674.0739.0
+ Purchases of Stock-in-Trade509.0559.0573.0586.0555.0
+ Changes in Inventories84.0-14.0-53.0-128.0-106.0
+ Employee Benefit Expense637.0629.0651.0725.0757.0
+ Finance Costs302.0305.0254.0213.0217.0
+ Depreciation & Amortisation251.0223.0217.0227.0226.0
+ Other Expenses802.0965.0836.0864.0847.0
Total Expenses3,103.03,287.03,090.03,161.03,235.0
EBITDA101.039.0393.0652.0772.0
EBIT-150.0-184.0176.0425.0546.0
Profit
PBT before Exceptional Items-330.0-406.0-16.0323.0451.0
+ Exceptional Items-294.0-14.00.0-85.012.0
Pretax Income-624.0-420.0-16.0238.0463.0
+ Current Tax12.016.07.018.021.0
+ Deferred Tax-15.036.034.021.028.0
Tax Expense-3.052.041.039.049.0
Net Income-621.0-472.0-57.0199.0414.0
+ Net Income — Continuing Ops-621.0-472.0-57.0199.0414.0
+ Other Comprehensive Income78.06.071.0419.0285.0
Total Comprehensive Income-543.0-466.014.0618.0699.0
Net Income to Common-559.0-463.0-47.0213.0409.0
Minority Interest-62.0-9.0-10.0-14.05.0
Per Share
Basic EPS-38.79-32.05-3.0213.1225.20
Diluted EPS-38.79-32.05-3.0213.1025.19
Other Comprehensive Income — detail
+ Other Comprehensive Income——71.0419.0285.0
+ Items NOT to be Reclassified to P&L-9.0-8.0-5.070.070.0
+ Items to be Reclassified to P&L87.014.076.0349.0215.0
Comprehensive Income — Owners of Parent-498.0-461.013.0581.0648.0
Comprehensive Income — Non-controlling Interests-45.0-5.01.037.051.0
Per Share — as-filed variants
Basic EPS — Continuing Operations-38.79-32.05-3.0213.1225.20
Diluted EPS — Continuing Operations-38.79-32.05-3.0213.1025.19
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1,540.01,633.01,880.02,241.02,376.0
Gross Margin %58.0958.3662.4266.4466.67
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-330.0-406.0-16.0323.0451.0
− Exceptional Items (reconciliation)-294.0-14.00.0-85.012.0
Net Income Adj (tax-effected)-328.4-458.0-57.0270.1403.3
EPS Adj-20.51-31.10-3.0217.8124.55
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value5.005.005.005.005.00
Paid Up Equity Capital72.077.081.081.081.0
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.